Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

diabetes glucose chronic disease biotech pharma review

News and Trends 14 Jun 2016

Could this be the ‘Beginning of the end’ for Diabetes? Let’s Review.

Given the rates of diabetes reaching ‘epidemic proportions’, we figured it was time to have a better overview of biotech’s progress in the field. With some serious advances having been made in the treatment of the disease, we have to ask – how much further can biotech go in the treatment of diabetes? It is important […]

June 14, 2016 - 9 minutesmins - By Dani Bancroft

ziarco atopic dermatitis psoriasis skin inflammation

News and Trends 14 Jun 2016

British Biotech startup shows 50% improvement in Atopic Dermatitis

Ziarco has received positive results from a Phase II trial with its leading candidate, which has shown to improve symptoms of atopic dermatitis by 50%, giving it the potential to fill the current need for a safe oral treatment for this inflammatory skin disease. Ziarco is a private biotech with a clinical-stage pipeline for inflammatory skin […]

June 14, 2016 - 2 minutesmins - By Denise Neves Gameiro

text mininig rights direct abstract

News and Trends 14 Jun 2016

Unlock the power of Text-mining tools

It has become clear that text mining is a great tool for rapid analysis of large volumes of biomedical literature. It delivers valuable information that helps to improve the accuracy and speed of the R&D process, as well as creating the opportunity to make more informed business decisions. As we’ve seen in our previous articles, text […]

June 14, 2016 - 4 minutesmins - By Jerome Topsent

kings college depression biomarker diagnostic

News and Trends 14 Jun 2016

New Biomarkers could make Personalized Medicine for Depression

Researchers from King’s College London have succeeded in developing a blood test that can help choose the best treatment for depression patients – a big improvement over the current trial-and-error approach. Depression doesn’t seem to be a particularly popular indication for biotechs, unlike other nervous systems diseases that reached significant milestones in the last year. Moreover, one […]

June 14, 2016 - 3 minutesmins - By Denise Neves Gameiro

synbio synthetic biology paillasse deinove indiebio biohacking polack

News and Trends 13 Jun 2016

“A new generation of Bio-entrepreneurs is rising right now” – SynBio in Europe

Our SynBio panel had a really popular turn-out at Labiotech Refresh. Chaired by Cathal Garvey, the Program Director at IndieBio EU, we had some very diverse leaders in the field present, from Biohackers to the CEO of Biofuel giant, Deinove. Asides Cathal, on the panel we had Axel Polack, a General Partner at the Joint Polish […]

June 13, 2016 - 4 minutesmins - By Dani Bancroft

diabetes biohub islet ospedale niguarda

News and Trends 13 Jun 2016

Italy cures Diabetes with new Engineered Mini-organs

Ospedale Niguarda Ca’ Granda has succeeded in treating a patient with type 1 diabetes, using a new tissue engineering techniques for more effective islet transplants – something that could bring this diabetes cure to more patients. Biotech is tackling diabetes from several fronts – from mitigation of symptoms, for example, Avita’s skin spray, to medtech inventions […]

June 13, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

immunocore oxford immtav tcr hiv

News and Trends 13 Jun 2016

Immunotherapy reaches Breakthrough in eliminating HIV

Immunocore has published key results for its new preclinical candidate for HIV, ImmTAV. This TCR-based immunotherapy has succeeded in targeting T-cells where HIV infection often ‘hides’ from drugs. Just after presenting promising results from its leading candidate at ASCO 2016 (read our coverage here), Immunocore is making headlines in another area – infectious disease. The […]

June 13, 2016 - 3 minutesmins - By Denise Neves Gameiro

vaccination gates foundation vaccine delivery

News and Trends 10 Jun 2016

Gates Foundation is funding EU Biotech to make Vaccines more affordable

Batavia Biosciences has won a €3.3M grant from the Gates Foundation, to fund new research in making cell culture cheaper – and drive down the price of some key vaccines. Within its goal of pushing science forward and bringing to developing countries, the Gates Foundation has outlined vaccine delivery as a key part of its strategy. […]

June 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

crispr therapeutics muscle stem cells anagenesis

News and Trends 10 Jun 2016

CRISPR Thx in yet another Collaboration, this time for Muscle Dystrophy

CRISPR Therapeutics has struck a deal with Anagenesis Biotechnologies, which has key technology for muscle stem cells. Together, they will tackle muscle disorders – including the rare disease Duchenne Muscular Dystrophy (DMD). CRISPR Therapeutics (Basel, Switzerland) is the European champion of gene editing for health applications, a field that promises to revolutionize therapies – even if […]

June 10, 2016 - 3 minutesmins - By Denise Neves Gameiro

biotech week genticel header

News and Trends 10 Jun 2016

Genticel is vaccinating against Cervical Cancer AFTER Infection

Estonia, our previous destination by the Baltic Sea, was a delightful and a full of potential place to visit. This week, we are heading down to the relaxing and sunny south of France, more precisely to Toulouse, once the capital of the Visigothic Kingdom and current to the Midi-Pyrénées region, the largest region in metropolitan France. It […]

June 10, 2016 - 2 minutesmins - By Joachim Eeckhout

asco biotech morphosys cancer chicago 2016 researh pharma

News and Trends 9 Jun 2016

How was it inside the ‘World Most Important Cancer Meeting’ of the Year?

Every year by the end of May/beginning of June, up to 30,000 of healthcare professionals head to Chicago to discuss the most recent advancements in Cancer treatments. Here, the MorphoSys team, which included Claudia Gutjahr-Löser and Jochen Orlowski, give you a sneak-insiders look into one of the most essential Cancer conferences of the year… You can also […]

June 9, 2016 - 4 minutesmins - By Dani Bancroft

inflarx cardiac surgery ifx1 anti c5a

News and Trends 9 Jun 2016

German Biotech launches Phase II in a hot Target for Inflammation

InflaRx has treated the first patient in a new Phase II trial, which is studying the potential of its anti-complement antibody in avoiding immunological complications after complex cardiac surgery – a big unmet need. It is competing with world most expensive drug Soliris from Alexion (US). Based in Jena (Germany), InflaRx specializes in developing new […]

June 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT